Abstract
Recent advances in molecular biology have identified numerous steps and proteins involved in malignant transformation as targets of anticancer therapy. Many molecular targeted agents are now undergoing clinical development. Successful developments of trastuzumab in treating breast cancer, imatinib in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs), and bevacizumab in colorectal cancer, have validated the concept of molecular targeting and raised expectations of patients and oncologists alike. Despite these successes, many agents, notably matrix metalloproteinase inhibitors (MMPIs), have failed in their development. In this review, we will address several issues related to tumor biology and clinical trial design that might have contributed to these successes and failures, and discuss strategies to best optimize the development of these novel agents.
Current Pharmaceutical Design
Title: Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions
Volume: 11 Issue: 2
Author(s): Eric X. Chen and Lillian L. Siu
Affiliation:
Abstract: Recent advances in molecular biology have identified numerous steps and proteins involved in malignant transformation as targets of anticancer therapy. Many molecular targeted agents are now undergoing clinical development. Successful developments of trastuzumab in treating breast cancer, imatinib in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs), and bevacizumab in colorectal cancer, have validated the concept of molecular targeting and raised expectations of patients and oncologists alike. Despite these successes, many agents, notably matrix metalloproteinase inhibitors (MMPIs), have failed in their development. In this review, we will address several issues related to tumor biology and clinical trial design that might have contributed to these successes and failures, and discuss strategies to best optimize the development of these novel agents.
Export Options
About this article
Cite this article as:
Chen X. Eric and Siu L. Lillian, Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions, Current Pharmaceutical Design 2005; 11 (2) . https://dx.doi.org/10.2174/1381612053382205
DOI https://dx.doi.org/10.2174/1381612053382205 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiepileptics and the Treatment of Neuropathic Pain: Evidence from Animal Models
Current Pharmaceutical Design CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Microtubules in Apoptosis Induction: Are They Necessary?
Current Cancer Drug Targets Immune Checkpoint Inhibitors: Basics and Challenges
Current Medicinal Chemistry Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors
Current Neuropharmacology Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design Intraperitoneal Chemotherapy as Primary Treatment of Advanced Ovarian Cancer:Efficacy, Toxicity, and Future Directions
Reviews on Recent Clinical Trials Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Anti-Cancer Agents in Medicinal Chemistry Steroid Regulation of Drug-Metabolizing Cytochromes P450
Current Drug Metabolism Monocarboxylate Transporter 1 in Brain Diseases and Cancers
Current Drug Metabolism Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry Matrix Metalloproteinase Dependent Cleavage of Cell Adhesion Molecules in the Pathogenesis of CNS Dysfunction with HIV and Methamphetamine
Current HIV Research Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry Classification of Human Pregnane X Receptor (hPXR) Activators and Non-Activators by Machine Learning Techniques: A Multifaceted Approach
Combinatorial Chemistry & High Throughput Screening Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets Emerging Role of Stromal Fibroblasts in Epithelial Cancer
Current Signal Transduction Therapy An Overview on Pyranocoumarins: Synthesis and Biological Activities
Current Organic Chemistry Long Term Recovery of Diaphragmatic Function in a Patient with Unilateral Diaphragmatic Pacemaker
Current Respiratory Medicine Reviews